Patients with haematological malignancies are at increased risk of severe disease and death from coronavirus disease 2019 . 1 Vaccination is essential to increase population immunity and decrease disease burden. The first COVID-19 vaccines were authorised in the UK after phase III trials, which showed that both the BNT162b2 (Pfizer-BioNTech) and ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines were effective at preventing symptomatic disease and hospitalisation. 2,3 Whilst both vaccines have demonstrated robust immune responses in healthy volunteers, patients with haematological malignancies were excluded from clinical trials. Emerging data suggest such patients are less likely to mount a humoral immune response to COVID-19 vaccination, with those who have received Bruton tyrosine kinase inhibitors (BTKi) or cluster of differentiation (CD)20directed therapies for B-cell malignancies a particularly highrisk group. [4][5][6][7] We report interim results from 55 participants recruited to our ongoing COV-VACC study, exploring the immune response to COVID-19 vaccination in patients with B-cell malignancies (South Central Berkshire B Research Ethics Committee and UK Health Research Authority approval IRAS number: 294547). Patients on treatment or treated within the last 24 months for a B-cell malignancy and receiving either the BNT162b2 (Pfizer-BioNTech; n = 41) or ChA-dOx1 nCoV-19 (Oxford-AstraZeneca; n = 14) vaccines were recruited. The median (range) age of participants was 60 (27-82) years and 50% were receiving systemic anti-cancer therapy (SACT) at the time of vaccination (Fig 1A , B).Blood samples were taken before vaccination and 1 month after the first and second vaccine doses. At each time-point, a full blood count and enumeration of whole blood

The pharmacokinetics and tissue penetration (as measured by a blister fluid model) of cefpirome were studied in six male volunteers following a 1 g intravenous dose. A mean peak serum concentration (at 5 min) of 97.4 mg/l was followed by rapid distribution into an apparent volume of 21.3 1. The serum elimination half-life was 2.3 h. Cefpirome penetrated rapidly into inflammatory fluid with a mean peak concentration of 39.2 mg/l at 1.9 h. The mean inflammatory fluid elimination half-life was 2.5 h. The availability of the drug in inflammatory fluid was high with a mean per cent penetration of 123%. The plasma and renal clearances were 109.5 and 82.1 ml/min respectively. Twenty-four hour urinary recovery was 75.5% of the administered dose. This study suggests that a twice daily dosage may be sufficient to treat tissue infections with susceptible pathogens.

No abstract

No abstract